Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350648 | 0.85 | CYP1A2 (0.43) | GAAALDH1A1MAPTHTTMAPK14 | |
| SCHEMBL6085223 | 0.85 | ALDH1A1 (0.40) | MEN1KMT2ATAAR1GAAALDH1A1 | |
| SCHEMBL26406461 | 0.79 | TAAR1 (0.42) | MEN1KMT2ASMN1; SMN2TAAR1GAA | |
| SCHEMBL3842935 | 0.79 | PTGS2 (0.39) | MEN1KMT2ASMN1; SMN2TAAR1GAA | |
| SCHEMBL11656144 | 0.78 | ACHE (0.44) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL5047053 | 0.78 | LCK (0.40) | MEN1KMT2ASMN1; SMN2GAAPTGS2 | |
| SCHEMBL11663327 | 0.78 | MAPK14 (0.49) | MEN1KMT2ASMN1; SMN2GAAPTGS2 | |
| SCHEMBL9228613 | 0.77 | KCNH2 (0.46) | MEN1KMT2ASMN1; SMN2TAAR1GAA | |
| SCHEMBL2104146 | 0.76 | MAPK14 (0.39) | KMT2AGAAALDH1A1MAPTHTT | |
| SCHEMBL13497802 | 0.76 | HDAC1 (0.43) | KMT2AGAAALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637432-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240010634-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2024-01-11 | — | — | US | disclosed |
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-28 | — | — | US | disclosed |
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| WO-2023016528-A1 | CLASS OF BENZOMORPHOLINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京明德新药研发有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2022036310-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036312-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036313-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3328496-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-2192838-A1 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009023272-A1 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | MEN1 2787/4885KMT2A 1532/4885SMN1; SMN2 3325/4885 |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | MEN1 2897/4885KMT2A 2137/4885SMN1; SMN2 4048/4885 |
| US-12630535-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | MEN1 3260/4885KMT2A 1987/4885SMN1; SMN2 2708/4885 |
| US-12637432-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TTK | MEN1 3559/4885KMT2A 2441/4885SMN1; SMN2 2727/4885 |
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | MEN1 2787/4885KMT2A 1532/4885SMN1; SMN2 3325/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | MEN1 2897/4885KMT2A 2137/4885SMN1; SMN2 4048/4885 |
| US-20240010634-A1 | PYRIMIDINYL SULFONAMIDES AS INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNKS2 | MEN1 3892/4885KMT2A 1376/4885SMN1; SMN2 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.